Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.39 |
| ▸ | PDE6D | O43924 | 4/20 | 0.39 |
| ▸ | PDE6A | P16499 | 4/20 | 0.39 |
| ▸ | PDE6G | P18545 | 4/20 | 0.39 |
| ▸ | PDE6B | P35913 | 4/20 | 0.39 |
| ▸ | PDE6C | P51160 | 4/20 | 0.39 |
| ▸ | PDE6H | Q13956 | 4/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985863 | 0.92 | PKM (0.35) | MEN1KMT2AGAAMAPTHPGD | |
| SCHEMBL3986662 | 0.91 | GAA (0.38) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL3985351 | 0.91 | POLB (0.36) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL3989304 | 0.90 | LMNA (0.41) | POLBMEN1KMT2AMAPTHPGD | |
| SCHEMBL3992564 | 0.90 | PDE5A (0.38) | PDE5APOLBMEN1KMT2AMAPT | |
| SCHEMBL3983532 | 0.90 | PKM (0.44) | KMT2AGAAMAPT | |
| SCHEMBL3983972 | 0.88 | RXFP1 (0.40) | ADORA1POLBMAPTHPGD | |
| SCHEMBL3986669 | 0.88 | TSHR (0.38) | MEN1KMT2AMAPT | |
| SCHEMBL3986060 | 0.87 | PDE5A (0.45) | PDE5AGAAMAPT | |
| SCHEMBL3981492 | 0.87 | MAOB (0.40) | ADORA1POLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | claimed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | claimed |
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | PDE5A 422/4885PDE6D 2534/4885PDE6A 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.